135 related articles for article (PubMed ID: 38240078)
1. Current gross examination and reporting patterns of post-neoadjuvant chemotherapy cystectomy specimens: Is it time for a standardized approach?
Saunders KE; Gerken N; Khani F; Williamson SR; Wobker SE
Am J Clin Pathol; 2024 May; 161(5):483-489. PubMed ID: 38240078
[TBL] [Abstract][Full Text] [Related]
2. Less Is More: Evaluation of Gross Examination Protocol for Cystectomy Specimens Following Neoadjuvant Chemotherapy.
Saunders KE; Cody Craig J; Hoerres DL; Maygarden SJ; Wobker SE
Am J Clin Pathol; 2022 Sep; 158(3):383-388. PubMed ID: 35608539
[TBL] [Abstract][Full Text] [Related]
3. Urothelial carcinoma in situ response to cisplatin-based neoadjuvant chemotherapy, or lack thereof: Impact on patient selection for organ preservation in muscle-invasive disease?
Tachibana I; Bandali E; Calaway AC; Krishnan N; Cheng L; Adra N; Kaimakliotis HZ
Urol Oncol; 2020 Nov; 38(11):850.e1-850.e7. PubMed ID: 32693973
[TBL] [Abstract][Full Text] [Related]
4. Role of Neoadjuvant Chemotherapy in Squamous Variant Histology in Urothelial Bladder Cancer: Does Presence and Percentage Matter?
Speir RW; Barboza MP; Calaway A; Masterson TA; Cary C; Koch M; Bihrle R; Cheng L; Adra N; Kaimakliotis H
Clin Genitourin Cancer; 2021 Feb; 19(1):47-52. PubMed ID: 32711961
[TBL] [Abstract][Full Text] [Related]
5. Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYS trial.
Hinsenveld FJ; Noordman BJ; Boormans JL; Voortman J; van Leenders GJLH; van der Pas SL; van Beek SC; Oprea-Lager DE; Vis AN
BMC Cancer; 2021 Oct; 21(1):1161. PubMed ID: 34715822
[TBL] [Abstract][Full Text] [Related]
6. Acceptance of Adjuvant and Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer in Germany: A Survey of Current Practice.
Dogan S; Hennig M; Frank T; Struck JP; Cebulla A; Salem J; Borgmann H; Klatte T; Merseburger AS; Kramer M; Hofbauer SL
Urol Int; 2018; 101(1):25-30. PubMed ID: 29510388
[TBL] [Abstract][Full Text] [Related]
7. Pathological T0 following radical cystectomy with or without neoadjuvant chemotherapy: a useful surrogate.
Lavery HJ; Stensland KD; Niegisch G; Albers P; Droller MJ
J Urol; 2014 Apr; 191(4):898-906. PubMed ID: 24300483
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology.
Vetterlein MW; Wankowicz SAM; Seisen T; Lander R; Löppenberg B; Chun FK; Menon M; Sun M; Barletta JA; Choueiri TK; Bellmunt J; Trinh QD; Preston MA
Cancer; 2017 Nov; 123(22):4346-4355. PubMed ID: 28743155
[TBL] [Abstract][Full Text] [Related]
9. Lack of Standardization in the Processing and Reporting of Post-Neoadjuvant Breast Cancer Specimens.
Han R; Regpala S; Slodkowska E; Nofech-Mozes S; Hanna W; Parra-Herran C; Lu FI
Arch Pathol Lab Med; 2020 Oct; 144(10):1262-1270. PubMed ID: 32142368
[TBL] [Abstract][Full Text] [Related]
10. The Rate of Neoadjuvant Chemotherapy Use in Muscle Invasive Bladder Cancer and The Approach of Urologists in Turkey.
Üçer O; Albaz AC; Atag E; Karaoglu A; Muezzinoglu T
Urol J; 2016 Oct; 13(5):2841-2844. PubMed ID: 27734426
[TBL] [Abstract][Full Text] [Related]
11. Patterns of Utilization and Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced-urothelial Bladder Cancer (LABC)-Real World Data From an Indian Tertiary Care Cancer Center.
Saravanabavan S; Prakash GJ; Joshi A; Pal M; Gujela A; Arora A; Bakshi G; Prabhash K; Noronha V; Murthy V; Maitre P; Teja R
Clin Genitourin Cancer; 2023 Oct; 21(5):e326-e333. PubMed ID: 37211451
[TBL] [Abstract][Full Text] [Related]
12. Pathological and Survival Outcomes Associated with Variant Histology Bladder Cancers Managed by Cystectomy with or without Neoadjuvant Chemotherapy.
Hajiran A; Azizi M; Aydin AM; Zemp L; Peyton CC; Dhillon J; Nealon S; Reich RR; Cao B; Li R; Manley BJ; Sexton WJ; Gilbert SM
J Urol; 2021 Jan; 205(1):100-108. PubMed ID: 32783489
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant Chemotherapy is Not Associated with Adverse Perioperative Outcomes after Robot-Assisted Radical Cystectomy: A Case for Increased Use from the IRCC.
Aldhaam NA; Elsayed AS; Jing Z; Richstone L; Wagner AA; Rha KH; Yuh B; Palou J; Khan MS; Menon M; Roupret M; Balbay D; Hosseini A; Wiklund P; Gaboardi F; Maatman TJ; Mottrie A; Wijburg C; Stöckle M; Hemal A; Kim E; Kaouk J; Hussein AA; Guru KA
J Urol; 2020 Jan; 203(1):57-61. PubMed ID: 31600114
[TBL] [Abstract][Full Text] [Related]
14. Tumor regression grade of urothelial bladder cancer after neoadjuvant chemotherapy: a novel and successful strategy to predict survival.
Fleischmann A; Thalmann GN; Perren A; Seiler R
Am J Surg Pathol; 2014 Mar; 38(3):325-32. PubMed ID: 24525502
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and toxicity considerations in the use of neoadjuvant chemotherapy for bladder cancer.
Narayan V; Vaughn D
Expert Opin Drug Metab Toxicol; 2015 May; 11(5):731-42. PubMed ID: 25604887
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of short-term outcomes of neoadjuvant chemotherapy followed by radical cystectomy in muscle-invasive bladder cancer: a single Egyptian institution experience.
Abdelrahman I; Aboulkassem H; Elazab A; Abdallah AY; Ismail Y; Taher M
J Egypt Natl Canc Inst; 2023 May; 35(1):13. PubMed ID: 37145329
[TBL] [Abstract][Full Text] [Related]
17. Survival and oncologic outcomes of complete transurethral resection of bladder tumor prior to neoadjuvant chemotherapy for muscle-invasive bladder cancer.
Pak JS; Haas CR; Anderson CB; DeCastro GJ; Benson MC; McKiernan JM
Urol Oncol; 2021 Nov; 39(11):787.e9-787.e15. PubMed ID: 33865688
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy in patients with invasive bladder cancer.
Vaughn DJ; Malkowicz SB
Urol Clin North Am; 2005 May; 32(2):231-7. PubMed ID: 15862620
[TBL] [Abstract][Full Text] [Related]
19. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
[TBL] [Abstract][Full Text] [Related]
20. Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT?
Brant A; Kates M; Chappidi MR; Patel HD; Sopko NA; Netto GJ; Baras AS; Hahn NM; Pierorazio PM; Bivalacqua TJ
Urol Oncol; 2017 Jan; 35(1):34.e17-34.e25. PubMed ID: 27639777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
